SNPMiner Trials (Home Page)
Report for Clinical Trial NCT01101438
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
This study is looking at whether Metformin, an agent that is commonly used to treat diabetes,
can decrease or affect the ability of breast cancer cells to grow and whether Metformin will
work with other therapies to keep cancer from recurring. Health Canada has not approved the
sale or use of Metformin to treat breast cancer, although they have approved its use in this
clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its
use in breast cancer is considered investigational.
Name: metformin hydrochloride
Description: Given orally
Type: Drug
Name: placebo
Description: Given orally
Type: Other
Primary Outcomes
Measure: Invasive disease-free survival in hormone receptor (ER and PgR) negative and positive (ER and/or PgR) sub-groups Time: 10 years
Secondary Outcomes
Measure: Overall survival Time: 10 years
Measure: Distant relapse-free survival Time: 10 years
Measure: Breast cancer-free interval Time: 10 years
Measure: Long-term clinical and laboratory safety Time: 10 years
Measure: Relevant medical endpoints (new diabetes, new cardiovascular hospitalizations) Time: 10 years
Measure: Health-related quality of life, physical activity, and diet Time: 10 years
Measure: Change in body mass index Time: 10 years
Measure: Correlative science outcomes Time: 10 years
Purpose: Treatment
Allocation: Randomized
Parallel Assignment
There is one SNP
SNPs
1 P13K
- Concurrent or planned participation in randomized trials of weight loss or exercise
interventions or trials targeting insulin, IGF-1 or their receptors, or involving P13K
inhibitors (at the time of randomization)*. --- P13K ---